<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Praluent¬Æ (alirocumab) - Comprehensive Profile | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        /* Custom animations matching your style */
        @keyframes fadeInRow {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        @keyframes pulse {
            0%, 100% { opacity: 0.5; transform: scale(0.95); }
            50% { opacity: 0.8; transform: scale(1.1); }
        }
        @keyframes slideIn {
            from { opacity: 0; transform: translateX(-10px); }
            to { opacity: 1; transform: translateX(0); }
        }
        .animate-fade-in-row { animation: fadeInRow 0.3s ease forwards; }
        .animate-pulse-glow { animation: pulse 3s ease-in-out infinite; }
        .animate-slide-in { animation: slideIn 0.6s ease-out forwards; }
        
        /* Staggered animations */
        .stagger-1 { animation-delay: 0.1s; }
        .stagger-2 { animation-delay: 0.2s; }
        .stagger-3 { animation-delay: 0.3s; }
        .stagger-4 { animation-delay: 0.4s; }
        
        /* Custom scrollbar */
        ::-webkit-scrollbar { width: 8px; height: 8px; }
        ::-webkit-scrollbar-track { @apply bg-gray-100 dark:bg-gray-800 rounded; }
        ::-webkit-scrollbar-thumb { @apply bg-gray-400 dark:bg-gray-600 rounded hover:bg-gray-500 dark:hover:bg-gray-500; }
        
        /* Glass effect */
        .glass {
            background: rgba(255, 255, 255, 0.75);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
        }
        .dark .glass {
            background: rgba(17, 24, 39, 0.75);
        }
    </style>
</head>
<body class="bg-gray-50 dark:bg-gray-900 transition-all duration-300">
    <!-- Fixed Header - Matching your Leaf Intelligence design -->
    <header class="fixed top-0 left-0 right-0 z-50 glass border-b border-gray-200 dark:border-gray-700 shadow-lg">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex justify-between items-center py-4">
                <!-- Logo -->
                <div class="flex items-center space-x-3">
                    <div class="relative">
                        <div class="h-12 w-12 bg-gradient-to-r from-green-400 to-cyan-400 rounded-lg flex items-center justify-center">
                            <span class="text-white text-2xl">üçÉ</span>
                        </div>
                        <div class="absolute inset-0 bg-gradient-to-r from-green-400 to-cyan-400 opacity-20 blur-xl animate-pulse-glow"></div>
                    </div>
                    <div>
                        <div class="text-xl font-light bg-gradient-to-r from-green-600 to-cyan-600 dark:from-green-400 dark:to-cyan-400 bg-clip-text text-transparent">
                            Leaf Intelligence
                        </div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 font-light">
                            Praluent Drug Profile
                        </div>
                    </div>
                </div>

                <!-- Navigation -->
                <nav class="hidden md:flex items-center space-x-1 bg-gray-100/50 dark:bg-gray-800/50 p-1.5 rounded-lg backdrop-blur-sm">
                    <a href="index.html" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Overview
                    </a>
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 bg-white dark:bg-gray-700 text-indigo-600 dark:text-indigo-400 shadow-md active">
                        Drug Profile
                    </button>
                    <a href="index.html#comparison" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Comparison
                    </a>
                </nav>

                <!-- Theme Toggle -->
                <button onclick="toggleTheme()" class="relative w-14 h-7 rounded-full bg-gray-200 dark:bg-gray-700 transition-all duration-300 shadow-inner hover:shadow-md">
                    <div class="absolute top-0.5 left-0.5 w-6 h-6 rounded-full bg-white dark:bg-gray-900 shadow-lg transform transition-transform duration-300 dark:translate-x-7 flex items-center justify-center">
                        <svg class="w-4 h-4 text-yellow-500 dark:hidden" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M12 7a5 5 0 100 10 5 5 0 000-10z"/>
                        </svg>
                        <svg class="w-4 h-4 text-indigo-400 hidden dark:block" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/>
                        </svg>
                    </div>
                </button>
            </div>
        </div>
    </header>

    <!-- Main Container with padding for fixed header -->
    <div class="pt-20 min-h-screen">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
            
            <!-- Hero Section -->
            <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-col md:flex-row justify-between items-start md:items-center gap-4">
                    <div>
                        <h1 class="text-4xl font-light mb-2 text-gray-900 dark:text-white">
                            Praluent¬Æ <span class="text-2xl text-gray-600 dark:text-gray-400">(alirocumab)</span>
                        </h1>
                        <p class="text-lg text-gray-600 dark:text-gray-400">
                            First PCSK9 Inhibitor Approved in US ‚Ä¢ Sanofi/Regeneron
                        </p>
                    </div>
                    <div class="flex flex-wrap gap-2">
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-green-500 to-emerald-500 text-white">
                            ‚úì FDA/EMA 2015
                        </span>
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-purple-500 to-pink-500 text-white">
                            üèÜ First PCSK9 mAb
                        </span>
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-blue-500 to-cyan-500 text-white">
                            üíâ Q2W/Q4W
                        </span>
                    </div>
                </div>
            </div>

            <!-- Tab Navigation -->
            <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-wrap gap-1 p-2">
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-indigo-600 text-white" onclick="showTab('overview', event)">
                        Overview
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('mechanism', event)">
                        Mechanism
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('regulatory', event)">
                        Regulatory
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('clinical', event)">
                        Clinical Trials
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('safety', event)">
                        Safety
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('market', event)">
                        Market
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('comparison', event)">
                        vs. Repatha
                    </button>
                </div>
            </div>

            <!-- Overview Tab -->
            <div class="tab-content active" id="overview">
                <!-- Key Alert -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-purple-50 to-pink-50 dark:from-purple-900/20 dark:to-pink-900/20">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-3">
                        üéØ First FDA-Approved PCSK9 Inhibitor
                    </h3>
                    <p class="text-gray-700 dark:text-gray-300 leading-relaxed">
                        Praluent was the first PCSK9 inhibitor approved by FDA (July 24, 2015), beating Repatha by 34 days. 
                        Unique among PCSK9 mAbs for showing nominal mortality benefit in ODYSSEY OUTCOMES trial (15% reduction, p=0.026).
                        Offers lower starting dose (75 mg) for better tolerability and titration flexibility.
                    </p>
                    <div class="mt-4 flex gap-4">
                        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s028lbl.pdf" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            FDA Label ‚Üí
                        </a>
                        <a href="https://clinicaltrials.gov/search?cond=Hypercholesterolemia&intr=alirocumab" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            Live Trials ‚Üí
                        </a>
                    </div>
                </div>

                <!-- Key Metrics Grid -->
                <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-4 gap-6 mb-8">
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-indigo-600 to-purple-600 bg-clip-text text-transparent mb-2">
                            50-60%
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">LDL-C Reduction</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">45-60% range</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-green-600 to-emerald-600 bg-clip-text text-transparent mb-2">
                            15%
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Mortality Reduction</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Only PCSK9i with benefit</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-amber-600 to-orange-600 bg-clip-text text-transparent mb-2">
                            75 mg
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Starting Dose</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Lower than competitors</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-purple-600 to-pink-600 bg-clip-text text-transparent mb-2">
                            $5,850
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Annual Cost</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">60% price cut from launch</div>
                    </div>
                </div>

                <!-- Detailed Info Cards -->
                <div class="grid grid-cols-1 lg:grid-cols-3 gap-8">
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm">üíä</span>
                            Dosing & Administration
                        </h3>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                <strong>Starting:</strong> 75 mg Q2W SC (titratable)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                <strong>Titrated:</strong> 150 mg Q2W if needed
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                <strong>Alternative:</strong> 300 mg Q4W (monthly)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                <strong>HoFH:</strong> 150 mg Q2W maximum
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                <strong>Pediatric:</strong> Weight-based (8+ years)
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://products.sanofi.us/praluent/praluent.html" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                Prescribing Information ‚Üí
                            </a>
                        </div>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-green-600 to-emerald-600 rounded-full flex items-center justify-center text-white text-sm">üìä</span>
                            Key Differentiators
                        </h3>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                First PCSK9i FDA approval (July 2015)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Only PCSK9i with mortality benefit
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Lower starting dose option (75 mg)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Q4W dosing available (300 mg)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚ßó</span>
                                Patent expiry 2027-2028
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1801174" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                ODYSSEY OUTCOMES Paper ‚Üí
                            </a>
                        </div>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-amber-600 to-orange-600 rounded-full flex items-center justify-center text-white text-sm">üë•</span>
                            Patient Populations
                        </h3>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Üí</span>
                                HeFH (heterozygous FH)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Üí</span>
                                HoFH (homozygous FH) - 2021
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Üí</span>
                                Clinical ASCVD
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Üí</span>
                                CV risk reduction - 2019
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Üí</span>
                                Pediatric 8+ years - 2024
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/praluent" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                EMA Assessment ‚Üí
                            </a>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Mechanism Tab -->
            <div class="tab-content hidden" id="mechanism">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">PCSK9 Inhibition via Monoclonal Antibody</h3>
                    <div class="prose prose-sm max-w-none text-gray-600 dark:text-gray-400">
                        <p class="mb-4">
                            Praluent is a fully human monoclonal antibody with high affinity binding to circulating PCSK9, 
                            preventing its interaction with LDL receptors on hepatocytes.
                        </p>
                        <ul class="space-y-2 ml-4">
                            <li><strong>Mechanism:</strong> Prevention of PCSK9-mediated LDL-R degradation</li>
                            <li><strong>Effect:</strong> Increased LDL-R density on liver cell surface</li>
                            <li><strong>Result:</strong> Enhanced uptake and catabolism of LDL-C</li>
                            <li><strong>Reduction:</strong> Substantial serum LDL-C reductions (50-60%)</li>
                            <li><strong>Onset:</strong> Rapid onset within days, peak effect by 4-8 weeks</li>
                        </ul>
                    </div>
                </div>

                <!-- Dosing Cards -->
                <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6 mb-8">
                    <div class="glass rounded-xl p-6 border-2 border-purple-500 dark:border-purple-400 hover:shadow-lg transition-all bg-gradient-to-r from-purple-50 to-pink-50 dark:from-purple-900/20 dark:to-pink-900/20">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">75 mg</div>
                        <div class="text-xl font-medium text-purple-600 dark:text-purple-400">Starting Dose</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Every 2 weeks (Q2W)<br>Lower than competitors</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-all">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">150 mg</div>
                        <div class="text-xl font-medium text-indigo-600 dark:text-indigo-400">Titrated Dose</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Q2W if LDL-C target not met<br>(e.g., <70 mg/dL)</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-all">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">300 mg</div>
                        <div class="text-xl font-medium text-indigo-600 dark:text-indigo-400">Alternative</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Every 4 weeks (Q4W)<br>Two 150 mg injections</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-all">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">12-26</div>
                        <div class="text-xl font-medium text-amber-600 dark:text-amber-400">Annual Injections</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">More than inclisiran (2-3)<br>Less than daily orals</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-all">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">150 mg</div>
                        <div class="text-xl font-medium text-green-600 dark:text-green-400">HoFH Dosing</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Q2W maximum<br>Lower efficacy (LDL-R dependent)</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-all">
                        <div class="text-2xl font-bold text-gray-900 dark:text-white mb-2">8+ years</div>
                        <div class="text-xl font-medium text-green-600 dark:text-green-400">Pediatric</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Weight-based dosing<br>HeFH/HoFH patients</div>
                    </div>
                </div>

                <div class="glass rounded-xl p-4 border-l-4 border-indigo-500 bg-indigo-50 dark:bg-indigo-900/20">
                    <p class="text-sm text-gray-700 dark:text-gray-300">
                        <strong>Key Differentiators:</strong> Acts extracellularly in plasma with rapid onset compared to inclisiran's delayed gene-silencing mechanism. 
                        Equivalent to evolocumab in PCSK9 inhibition potency but offers lower starting dose for titration flexibility.
                    </p>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div class="tab-content hidden" id="regulatory">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">FDA Approval Timeline</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                        
                        <!-- Timeline items -->
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-gradient-to-r from-green-50 to-emerald-50 dark:from-green-900/20 dark:to-emerald-900/20 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">JULY 24, 2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Initial FDA Approval - FIRST PCSK9i</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    First PCSK9 inhibitor approved in US. For HeFH and clinical ASCVD as adjunct to diet/statins.
                                </div>
                                <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-praluent-treat-certain-patients-high-cholesterol" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    FDA Announcement ‚Üí
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">APRIL 26, 2019</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">CV Outcomes Indication</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Label expansion for MI, stroke, and unstable angina reduction based on ODYSSEY OUTCOMES trial showing mortality benefit.
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">APRIL 1, 2021</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">HoFH Indication</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Expanded to adults with homozygous familial hypercholesterolemia as adjunct to other therapies.
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">MARCH 11, 2024</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Pediatric Expansion</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Age limit lowered to 8+ years for HeFH patients, younger than competitor approvals.
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-amber-50 dark:bg-amber-900/20 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2025</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Latest Updates</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Updated pregnancy/lactation data from registries. No fetal harm signals but discontinuation advised. No new restrictions.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">EMA Approval Timeline</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-blue-300 dark:via-blue-600 to-transparent"></div>
                        
                        <!-- Timeline items -->
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">SEPTEMBER 23, 2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">EMA Marketing Authorization</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Broader initial indication than FDA, including statin-intolerant patients. For primary hypercholesterolemia and mixed dyslipidemia.
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">MARCH 15, 2019</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">CV Risk Reduction</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Expanded for CV risk reduction in adults with established atherosclerotic CVD.
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">2021</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">HoFH Addition</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Added indication for homozygous familial hypercholesterolemia in adults.
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">2023-2024</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Pediatric Extension</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Extended to ages 8+ for HeFH/HoFH. Continuous PBRERs show no new safety signals.
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">OCTOBER 2023</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Latest Revision</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    2025 confirmations via variation reports. No withdrawals, though pricing negotiations ongoing in France.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div class="tab-content hidden" id="clinical">
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700 mb-8">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">ODYSSEY Clinical Development Program</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Trial Name</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Phase</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">N</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Year</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Primary Endpoint</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Results</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Data</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">DF490336</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-gray-100 dark:bg-gray-900/30 text-gray-800 dark:text-gray-400">Phase 1</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">183</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2013</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">PK/PD</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">LDL-C reductions up to 72%</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01288443" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY MONO</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">103</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2014</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change at week 24</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">47% reduction vs ezetimibe</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01644474" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY COMBO I/II</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">1,036</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2014</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change at week 24</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">48-50% reduction with statins</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01644175" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY FH I/II</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">735</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2015</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change (HeFH)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">~58% reduction in HeFH</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01623115" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY LONG TERM</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2,341</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2015</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change at week 24</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">61% reduction; MACE HR 0.52</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01507831" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="bg-gradient-to-r from-blue-50 to-purple-50 dark:from-blue-900/10 dark:to-purple-900/10">
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">ODYSSEY OUTCOMES</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-600 dark:text-gray-400">18,924</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-600 dark:text-gray-400">2018</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-600 dark:text-gray-400">MACE (CV death, MI, stroke, UA)</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-600 dark:text-gray-400">HR 0.85 (15% RRR); Mortality HR 0.85 (p=0.026)</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01663402" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs font-bold">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY HoFH</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">69</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2020</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change (HoFH)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">36% reduction</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT03156621" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white font-medium">ODYSSEY KIDS</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">42</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2024</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C change (pediatric)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">35-46% reduction</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT02890992" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View ‚Üí</a>
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <!-- Efficacy Chart -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-6">ODYSSEY OUTCOMES Results</h3>
                    <div class="grid grid-cols-2 md:grid-cols-3 lg:grid-cols-6 gap-6">
                        <div class="text-center">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">55%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">LDL-C Reduction<br>(OUTCOMES)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-purple-600 dark:text-purple-400">61%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">LDL-C Reduction<br>(LONG TERM)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">53 mg/dL</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">Median LDL<br>Achieved</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-blue-600 to-cyan-600 bg-clip-text text-transparent">15%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">All-Cause Mortality<br>Reduction (p=0.026)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">15%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">MACE Reduction<br>(Overall)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-red-600 dark:text-red-400">24%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">MACE Reduction<br>(LDL ‚â•100 mg/dL)</div>
                        </div>
                    </div>
                    <div class="mt-6 p-4 bg-green-50 dark:bg-green-900/20 rounded-lg">
                        <p class="text-sm text-gray-700 dark:text-gray-300">
                            <strong>Unique Finding:</strong> ODYSSEY OUTCOMES showed nominal mortality benefit not seen with evolocumab (FOURIER). 
                            Greatest benefit in patients with baseline LDL ‚â•100 mg/dL: MACE 24% RRR, death 29% RRR. Median follow-up 2.8 years.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div class="tab-content hidden" id="safety">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Safety Overview</h3>
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-6">
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">1.5-2M</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Patient-years exposure</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">None</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Black Box Warnings</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">~2%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Discontinuation rate</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">~5%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Anti-drug antibodies</div>
                        </div>
                    </div>
                </div>

                <div class="grid grid-cols-1 lg:grid-cols-3 gap-8">
                   <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm">1</span>
                            Most Common AEs
                        </h4>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Nasopharyngitis</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">11.3%</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Injection site reactions</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">7.2%</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Upper respiratory infection</span>
                                <span class="font-medium text-gray-600 dark:text-gray-400">5.7%</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Influenza</span>
                                <span class="font-medium text-gray-600 dark:text-gray-400">5.7%</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Myalgia</span>
                                <span class="font-medium text-gray-600 dark:text-gray-400">5.4%</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>UTI</span>
                                <span class="font-medium text-gray-600 dark:text-gray-400">4.8%</span>
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s028lbl.pdf#page=12" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                FDA Safety Data ‚Üí
                            </a>
                        </div>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-amber-600 to-orange-600 rounded-full flex items-center justify-center text-white text-sm">2</span>
                            Injection Site Reactions
                        </h4>
                        <p class="text-sm text-gray-600 dark:text-gray-400 mb-3">
                            Overall incidence: 7.2% (vs 5.1% placebo)
                        </p>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Pruritus</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">Most common</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Erythema</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">Common</span>
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex justify-between">
                                <span>Pain</span>
                                <span class="font-medium text-gray-600 dark:text-gray-400">Less common</span>
                            </li>
                        </ul>
                        <div class="mt-3 p-3 bg-amber-50 dark:bg-amber-900/20 rounded-lg">
                            <p class="text-xs text-gray-700 dark:text-gray-300">
                                Higher than Repatha (5.7%) but generally mild
                            </p>
                        </div>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-green-600 to-emerald-600 rounded-full flex items-center justify-center text-white text-sm">3</span>
                            Special Populations
                        </h4>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong>Pregnancy:</strong> No fetal harm signals in registries; discontinuation advised
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong>Lactation:</strong> Limited data available
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong>Statin-Intolerant:</strong> 45% LDL-C reduction, well-tolerated (ALTERNATIVE trial)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong>Pediatric (8+):</strong> 35-46% LDL reduction, similar safety to adults
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://clinicaltrials.gov/study/NCT02890992" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                ODYSSEY KIDS Trial ‚Üí
                            </a>
                        </div>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 mt-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Long-Term Safety Data</h3>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Neurocognitive Effects:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>‚Ä¢ Neurocognitive AEs: 1.2% vs 0.7% placebo</li>
                                <li>‚Ä¢ No association with LDL <25 mg/dL</li>
                                <li>‚Ä¢ 2025 meta-analyses confirm no link</li>
                                <li>‚Ä¢ Rare reports non-causal</li>
                            </ul>
                        </div>
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Metabolic Effects:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>‚Ä¢ New-onset diabetes: HR 1.18 (slight increase)</li>
                                <li>‚Ä¢ Similar to statin effect</li>
                                <li>‚Ä¢ Ophthalmologic AEs: 1.3% (same as placebo)</li>
                                <li>‚Ä¢ No cataract increase</li>
                            </ul>
                        </div>
                    </div>
                    <div class="mt-4 p-4 bg-yellow-50 dark:bg-yellow-900/20 rounded-lg">
                        <p class="text-sm text-gray-700 dark:text-gray-300">
                            <strong>Real-World Evidence:</strong> 2025 data from Japan shows low AE rates consistent with trials. 
                            Benign profile in T1D patients. Similar to inclisiran but with more extensive long-term data.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div class="tab-content hidden" id="market">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Pricing & Access Evolution</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-green-300 dark:via-green-600 to-transparent"></div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-red-600 dark:text-red-400 mb-1">2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Launch Pricing</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block bg-red-100 dark:bg-red-900/30 text-red-800 dark:text-red-400 px-2 py-1 rounded mr-2">US: $14,000-14,600/year</span>
                                    <span class="inline-block bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400 px-2 py-1 rounded">EU: ~‚Ç¨5,000/year</span><br>
                                    Launch as first PCSK9 inhibitor with high pricing leading to immediate payer pushback
                                </div>
                                <a href="https://www.reuters.com/article/us-sanofi-cholesterol-idUSKCN0PY1NJ20150724" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    Launch News ‚Üí
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">2018-2019</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Price Reduction</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400 px-2 py-1 rounded mr-2">60% price cut to $5,850/year</span><br>
                                    Post-ODYSSEY OUTCOMES price reduction. Net ~$4,000 with rebates<br>
                                    <span class="inline-block bg-purple-100 dark:bg-purple-900/30 text-purple-800 dark:text-purple-400 px-2 py-1 rounded mt-1">Value-based contracts piloted</span>
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2019</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Partnership Restructure</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Partnership restructure: Regeneron takes US rights, Sanofi maintains ex-US<br>
                                    <span class="inline-block bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400 px-2 py-1 rounded mt-1">Copay cards: $50/month for eligible</span>
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2025</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Current Status</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400 px-2 py-1 rounded">Annual sales: ~$400-500M</span><br>
                                    Sales plateaued below Repatha. Competition from inclisiran and oral PCSK9i
                                </div>
                                <a href="https://www.sanofi.com/en/investors/financial-results-and-events" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    Financial Reports ‚Üí
                                </a>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-purple-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-purple-50 dark:bg-purple-900/20 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-purple-600 dark:text-purple-400 mb-1">2027-2028</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Patent Expiry</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Patent expiry approaching. Biosimilars expected (Samsung Bioepis in pipeline)<br>
                                    Projected 40-60% price reduction with biosimilar entry
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8 mb-8">
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Value-Based Contracting</h3>
                        <ul class="space-y-3 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                First PCSK9i with value-based contracts (2018)
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                Refunds for CV events while on therapy
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                Copay assistance programs ($50/month)
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                OOP costs dropped 50% post-price cut
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚Ä¢</span>
                                Medicare beneficiaries: $25-150/month
                            </li>
                        </ul>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Access Barriers</h3>
                        <ul class="space-y-3 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚Ä¢</span>
                                70-80% initial prior authorization denials
                            </li>
                            <li class="flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚Ä¢</span>
                                Requirements: statin intolerance/failure
                            </li>
                            <li class="flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚Ä¢</span>
                                High LDL threshold (>100-130 mg/dL)
                            </li>
                            <li class="flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚Ä¢</span>
                                CV risk documentation needed
                            </li>
                            <li class="flex items-start">
                                <span class="text-amber-500 mr-2 mt-1">‚Ä¢</span>
                                Uptake <5-10% of eligible patients
                            </li>
                        </ul>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Competitive Landscape</h3>
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="text-lg font-bold text-gray-900 dark:text-white">Repatha</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">PCSK9 mAb - Amgen</div>
                            <div class="text-xs text-indigo-600 dark:text-indigo-400 mt-2">Higher sales</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="text-lg font-bold text-gray-900 dark:text-white">Leqvio</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">siRNA - Novartis</div>
                            <div class="text-xs text-indigo-600 dark:text-indigo-400 mt-2">Twice-yearly</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="text-lg font-bold text-gray-900 dark:text-white">Oral PCSK9i</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Multiple</div>
                            <div class="text-xs text-indigo-600 dark:text-indigo-400 mt-2">Daily oral</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="text-lg font-bold text-gray-900 dark:text-white">Biosimilars</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Samsung et al.</div>
                            <div class="text-xs text-indigo-600 dark:text-indigo-400 mt-2">2028+</div>
                        </div>
                    </div>
                    <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                        <a href="https://www.fiercepharma.com/pharma/pcsk9-market-analysis" target="_blank" class="text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                            Market Analysis ‚Üí
                        </a>
                    </div>
                </div>
            </div>

            <!-- Comparison Tab -->
            <div class="tab-content hidden" id="comparison">
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700 mb-8">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">Praluent vs. Repatha Head-to-Head</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Feature</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Praluent (alirocumab)</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Repatha (evolocumab)</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">FDA Approval</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">July 24, 2015 (FIRST)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">August 27, 2015</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Starting Dose</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">75 mg Q2W (titratable)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">140 mg Q2W (fixed)</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Alternative Dosing</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">300 mg Q4W</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">420 mg monthly</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Pediatric Age</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">8+ years</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">10+ years</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">LDL-C Reduction</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">50-60%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">50-70%</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Landmark Trial</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">ODYSSEY OUTCOMES (n=18,924)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">FOURIER (n=27,564)</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">MACE Reduction</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">15% (HR 0.85)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">15-20% (HR 0.85)</td>
                                </tr>
                                <tr class="bg-gradient-to-r from-blue-50 to-cyan-50 dark:from-blue-900/10 dark:to-cyan-900/10">
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">Mortality Benefit</td>
                                    <td class="px-6 py-4 text-sm font-bold text-green-600 dark:text-green-400">Yes (HR 0.85, p=0.026)</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-600 dark:text-gray-400">No (HR 1.04)</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">ISR Rate</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">7.2%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">5.7%</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Immunogenicity</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">5% ADA, <1% neutralizing</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">0.3% ADA, rare neutralizing</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">2025 Sales</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">~$400-500M</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">~$1.3B</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">List Price (2025)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">$5,850/year</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">$5,850/year</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Patent Expiry</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2027-2028</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Late 2027</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Key Advantage</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Lower starting dose, mortality signal</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Larger trial, lower ISR rate</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Consider Praluent When:</h3>
                        <ul class="space-y-3 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Lower starting dose desired for tolerability
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Titration flexibility needed
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Q4W dosing preferred (300 mg option)
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Younger pediatric patients (8+ vs 10+)
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2 mt-1">‚úì</span>
                                Very high-risk patients (mortality benefit)
                            </li>
                        </ul>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Consider Repatha When:</h3>
                        <ul class="space-y-3 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex items-start">
                                <span class="text-blue-500 mr-2 mt-1">‚úì</span>
                                Fixed dosing simplicity preferred
                            </li>
                            <li class="flex items-start">
                                <span class="text-blue-500 mr-2 mt-1">‚úì</span>
                                Lower injection site reaction risk important
                            </li>
                            <li class="flex items-start">
                                <span class="text-blue-500 mr-2 mt-1">‚úì</span>
                                Extensive long-term safety data desired
                            </li>
                            <li class="flex items-start">
                                <span class="text-blue-500 mr-2 mt-1">‚úì</span>
                                Monthly single-dose option needed
                            </li>
                            <li class="flex items-start">
                                <span class="text-blue-500 mr-2 mt-1">‚úì</span>
                                Lower immunogenicity concerns
                            </li>
                        </ul>
                    </div>
                </div>

                <div class="glass rounded-xl p-4 mt-8 border-l-4 border-green-500 bg-green-50 dark:bg-green-900/20">
                    <p class="text-sm text-gray-700 dark:text-gray-300">
                        <strong>Clinical Equivalence:</strong> Both agents are considered therapeutically equivalent for LDL-C reduction and CV risk reduction. 
                        Choice often based on formulary coverage, patient preference for dosing regimen, and individual tolerability. 
                        The mortality signal with Praluent may influence choice in highest-risk patients.
                    </p>
                </div>

                <div class="glass rounded-2xl p-6 mt-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Legacy Position</h3>
                    <p class="text-sm text-gray-600 dark:text-gray-400 mb-4">
                        Praluent pioneered PCSK9 inhibition as first FDA-approved agent. Mortality signal in ODYSSEY OUTCOMES remains unique differentiator. 
                        Focus shifting to Lp(a) inhibitors and next-generation lipid therapies.
                    </p>
                    <p class="text-sm text-gray-600 dark:text-gray-400">
                        <strong>Sales Performance Gap:</strong> Repatha outsells Praluent ~3:1 despite similar efficacy due to Amgen's stronger cardiovascular 
                        portfolio presence and better payer relationships. 2019 partnership restructure impacted Praluent momentum.
                    </p>
                    <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700 flex gap-4">
                        <a href="https://www.regeneron.com/pipeline-medicines" target="_blank" class="text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                            Regeneron Pipeline ‚Üí
                        </a>
                        <a href="https://www.sanofi.com/en/our-science/pipeline" target="_blank" class="text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                            Sanofi Pipeline ‚Üí
                        </a>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- JavaScript -->
    <script>
        function toggleTheme() {
            document.body.classList.toggle('dark');
            localStorage.setItem('theme', document.body.classList.contains('dark') ? 'dark' : 'light');
        }

        // Load saved theme
        if (localStorage.getItem('theme') === 'dark' || (!localStorage.getItem('theme') && window.matchMedia('(prefers-color-scheme: dark)').matches)) {
            document.body.classList.add('dark');
        }

        function showTab(tabName, event) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => {
                tab.classList.add('hidden');
                tab.classList.remove('active');
            });
            
            // Update button styles
            const buttons = document.querySelectorAll('.tab-btn');
            buttons.forEach(btn => {
                btn.classList.remove('bg-indigo-600', 'text-white');
                btn.classList.add('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            });
            
            // Show selected tab
            document.getElementById(tabName).classList.remove('hidden');
            document.getElementById(tabName).classList.add('active');
            
            // Style active button
            event.target.classList.remove('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            event.target.classList.add('bg-indigo-600', 'text-white');
        }
    </script>
</body>
</html>